ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

THE END OF THE ROAD FOR pMDIs?

Springboard's Finn Heraghty and Heather Jameson explore the extent to which the healthcare needs of a population could be covered by the combined use of soft mist inhalers and dry powder inhalers, and discuss the factors that will impact the continued importance of pressurised metered dose inhalers going forward.

CHALLENGES BESIDES DRUG TARGETING – REGULATORY HURDLES FOR MULTIDOSE NASAL SPRAYS

Marie-Christine Klein, Andreas Bilstein and Rouven Kraus, discuss recent regulatory changes affecting drug-device combination products, using the example of a multidose nasal spray.

DEVELOPING AN INHALABLE FORMULATION OF THE FIRST GENERATIVE AI DRUG

Brita Belli introduces Insilico Medecine’s inhalable formulation of its AI-designed therapy for the treatment of idiopathic pulmonary fibrosis, its progression through clinical trials and the company’s approach to generative AI in the pharmaceutical space more broadly.

SMART SCALING FOR SUCCESSFUL CAPSULE-BASED DRY POWDER INHALER FILLING USING DRUM TECHNOLOGIES

SMART SCALING FOR SUCCESSFUL CAPSULE-BASED DRY POWDER INHALER FILLING USING DRUM TECHNOLOGIES

Carolyn Berg, William Chin and Patrick Goncalves discuss the considerations for filling capsules for dry powder inhalers across the various stages of clinical trials and commercialisation, and how to tackle the challenges of scaling up filling processes.

SPRAY DELIVERY: TARGETING PATIENT NEEDS AND EXPECTATIONS WITH PRECISION

Gladys Corrons-Bouis

SPRAY DELIVERY: TARGETING PATIENT NEEDS AND EXPECTATIONS WITH PRECISION

Gladys Corrons-Bouis and Cyril Le Loc’h discuss the use of spray delivery for precise targeting of patient medication.

FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET

FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET

Ross Errington explores how pharmaceutical companies can evolve their pMDI drug products to make them fit for the future considering the several recent regulatory changes that are transforming the landscape of inhalation drugs.

BENEFITS OF INNOVATIVE COMPRESSED GAS-POWERED INTRANASAL DRUG DELIVERY DEVICES

BENEFITS OF INNOVATIVE COMPRESSED GAS-POWERED INTRANASAL DRUG DELIVERY DEVICES

Albie Lavin discusses the exciting potential of propellant-driven systems for intranasal delivery, and how Picocyl’s Pico-Cylinders provide the ideal mechanism to take advantage of this potential.

TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY

TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY

Mark Allen, Andrew Fiorini and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper.

NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY

Dr Richard Johnson

NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY

Richard Johnson explores the changing nasal delivery landscape, highlighting challenges in nasal drug formulation and potential methods to overcome them.

UNLOCKING THE POTENTIAL OF INTRANASAL DRUG DELIVERY

Silgan Dispensing

UNLOCKING THE POTENTIAL OF INTRANASAL DRUG DELIVERY

Allan Houston, Marcel Sachs and Heiko Rolland discuss the healthcare potential of intranasal drug delivery systems and the necessary steps for bringing these solutions to market.

PERFECT TIMING FOR THE AUTOMATION OF OINDP TESTING

Copley Scientific

PERFECT TIMING FOR THE AUTOMATION OF OINDP TESTING

Adam Smith and Clair Brooks take a look at the benefits of automation, focusing on the actuation of metered dose inhalers and multidose nasal sprays/aerosols.

SPRAYTEC LASER DIFFRACTION: ROBUST, REPRODUCIBLE DROPLET SIZE DATA

Malvern Panalytical

SPRAYTEC LASER DIFFRACTION: ROBUST, REPRODUCIBLE DROPLET SIZE DATA

Anne Virden discusses the benefits and applications of Malvern Panalytical's Spraytec laser diffraction system for the measurement of spray particles and droplets.

INTERVIEW: RDD EUROPE 2023 REVIEW & RDD 2024 PREVIEW

CONFERENCE SHOWCASE

INTERVIEW: RDD EUROPE 2023 REVIEW & RDD 2024 PREVIEW

Respiratory Drug Delivery talks with ONdrugDelivery, reviewing highlights of the successful RDD Europe 2023 event, which took place in Antibes, France last May, then describing what’s ahead for RDD 2024, which will take place in Tuscon, AZ, US, next May, including some of the key upcoming deadlines for participants.

EXPLORING THE PERFORMANCE OF LOW-GWP PROPELLANTS

Proveris Scientific

EXPLORING THE PERFORMANCE OF LOW-GWP PROPELLANTS

Grant Thurston and Lynn Jordan discusses the performance of pressurised metered dose inhaler propellants with a low global warming potential.

CUSTOMISABLE MESH NEBULISER PLATFORMS: VALUE IN COMBINATION PRODUCT DEVELOPMENT

Edgar Hernan Cuevas Brun

HCmed Innovations

CUSTOMISABLE MESH NEBULISER PLATFORMS: VALUE IN COMBINATION PRODUCT DEVELOPMENT

Edgar Hernan Cuevas Brun and Yuan-Ming Hsu look at the advantages of customisable nebuliser platforms for new combination products.

THE IMPORTANCE OF THE BREATHING MANOEUVRE IN NEBULISED THERAPIES

Carolina Dantas

THE IMPORTANCE OF THE BREATHING MANOEUVRE IN NEBULISED THERAPIES

Carolina Dantas and Ulf Krueger highlight the importance of the breathing manoeuvre in nebulised therapies – and describe a small study designed to test the effectiveness of patient feedback technology when it comes to guiding the inhalation manoeuvre.

TRANSFORMING PHARMA MANUFACTURING TO DRIVE SUSTAINABILITY AND COST EFFICIENCY

TRANSFORMING PHARMA MANUFACTURING TO DRIVE SUSTAINABILITY AND COST EFFICIENCY

Michael Astle, Gareth Jenkins and Edward Mayo explore current strategies to reduce carbon emissions and drive cost efficiency throughout the healthcare industry.

MAKING LOW-CARBON-EMISSION SINGLE-USE MEDICAL DEVICES A REALITY

Dr Veluska Bruce

MAKING LOW-CARBON-EMISSION SINGLE-USE MEDICAL DEVICES A REALITY

Veluska Bruce discusses the design and development of single-use autoinjectors in the context of sustainable development.

SUSTAINABILITY IN DRUG DELIVERY – STATE OF PLAY IN 2023

Isobel Filipova

SUSTAINABILITY IN DRUG DELIVERY – STATE OF PLAY IN 2023

Isobel Filipova of Owen Mumford explains where the healthcare industry stands on current environmental objectives, identifies obstacles to achieving sustainability in drug delivery and looks at how the sector can make progress to meet its objectives.

TIPS AND TRICKS FOR IMPLEMENTING SUSTAINABILITY INITIATIVES

TIPS AND TRICKS FOR IMPLEMENTING SUSTAINABILITY INITIATIVES

Henryk Badack outlines Vetter's efforts to establish sustainable business practices.

THE EVOLUTION OF THE PHARMA ECOSYSTEM: PRODUCT PERFORMANCE NOW MEETS SUSTAINABILITY

Dr Bettine Boltres

West Pharmaceutical Services

THE EVOLUTION OF THE PHARMA ECOSYSTEM: PRODUCT PERFORMANCE NOW MEETS SUSTAINABILITY

Bettine Boltres and Shivani Polasani discuss how pharma can progress towards a more sustainable future, and consider the role that the collaboration between Corning and West Pharmaceutical Services can play in supporting pharma’s sustainability goals.

DRIVING SUSTAINABLE DRUG DELIVERY DEVICES WITH CONTINUOUS IMPROVEMENT PROCESSES

DRIVING SUSTAINABLE DRUG DELIVERY DEVICES WITH CONTINUOUS IMPROVEMENT PROCESSES

Marc Severin discusses the H&T Excellence programme and how it has been expanded to include methods and training to help H&T Presspart identify environmental impact at a product group level and take co-ordinated action to reduce carbon emissions across the organisation.

GREEN THINKING: HOW TO BECOME A MORE SUSTAINABLE ORGANISATION

GREEN THINKING: HOW TO BECOME A MORE SUSTAINABLE ORGANISATION

André Jansen and Ron Cisliek describe how high-precision mould maker IGS GeboJagema is fostering a culture of “green thinking” and making sustainability a core part of its business.

ENVIRONMENTAL DRIVERS FOR CHANGE IN DRUG DELIVERY DEVICES

ENVIRONMENTAL DRIVERS FOR CHANGE IN DRUG DELIVERY DEVICES

Will Morris discusses the positive changes that have occurred when it comes to environmental sustainability in the medical industry, in the context of examining what more can be done.

SUSTAINABILITY UNLEASHED: DRIVING POSITIVE IMPACT IN THE PHARMA INDUSTRY

Justin Schroeder

PCI Pharma Services

SUSTAINABILITY UNLEASHED: DRIVING POSITIVE IMPACT IN THE PHARMA INDUSTRY

Justin Schroeder, Ann Cartwright and Gigi Bat-Erdene discuss the unique challenges facing the pharmaceutical industry in adopting environmental, social and governance principles, and present a way forward to achieve the necessary goal of improving sustainability within the industry.

SHAPING A SUSTAINABLE BIOPHARMA INDUSTRY

SHAPING A SUSTAINABLE BIOPHARMA INDUSTRY

Jimin Han delves into the intricate landscape of sustainability challenges within the biopharma industry and explores the innovative solutions that are steering drug development toward a greener future.

HOW LIFECYCLE ASSESSMENT SUPPORTS INSIGHT-DRIVEN SUSTAINABLE DESIGN

Paramesh Natarajan

HOW LIFECYCLE ASSESSMENT SUPPORTS INSIGHT-DRIVEN SUSTAINABLE DESIGN

Paramesh Natarajan, Shadi Bavar and Charlie Dean present the case for using screening lifecycle assessments to lead into more detailed targeted and comprehensive lifecycle assessments focused on the areas of greatest environmental impact, using a screening lifecycle assessment of a hypothetical body-worn injector as an example.

AN AUTOINJECTOR REVOLUTION: ADVANCED SIMULATION TECHNOLOGIES ENHANCING GLOBAL MANUFACTURING NETWORKS

INDUSTRIALISATION

Edwin Hendrawan

AN AUTOINJECTOR REVOLUTION: ADVANCED SIMULATION TECHNOLOGIES ENHANCING GLOBAL MANUFACTURING NETWORKS

Edwin Hendrawan, Yi-Chi Lu and Christian Walter set out how SHL is building simulation capabilities, and describe how simulation will propel the business forward on every level, from individual shop floors to overall global expansion planning, in order to be able to meet the growing and increasingly complex demands from both pharma customers and patients.

INTERVIEW with Jeff Henderson

INTERVIEW with Jeff Henderson

Jeff Henderson discusses the practice of outsourcing within the pharmaceutical industry. He considers factors that pharma and biopharma companies should consider when determining whether or not to outsource to a CDMO and many of the advantages that outsourcing can offer, especially to small- and medium-sized companies.

AUTOINJECTORS FOR LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY

AUTOINJECTORS FOR LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY

Ian Thompson provides a summary of a recent literature review on subcutaneous administration with dose volumes greater than 1.0 mL, which examines how previous studies have addressed the limitations and considerations for designing and developing large-volume autoinjectors.

Interview with Claire Raynal-Olive & Pierre-Yves Favennec

Claire Raynal-Olive

Interview with Claire Raynal-Olive & Pierre-Yves Favennec

Claire Raynal-Olive and Pierre-Yves Favennec discuss the strategy and objectives of Aptar Pharma’s expansion programme of its global rubber component manufacturing, implementing advanced technology, increased capacity and local-for-local manufacturing capability.

AUTOMATING ASSEMBLY TO EXPEDITE TIME-TO-MARKET

INDUSTRIALISATION

Dr Dave Seaward

AUTOMATING ASSEMBLY TO EXPEDITE TIME-TO-MARKET

Dave Seaward discusses how 3P innovation takes a holistic approach to solving the technical challenges encountered by its clients and looks for opportunities to enhance the final product, enable efficient processing and support commercially viable manufacturing.

COMPANY SHOWCASE: PCI PHARMA SERVICES

INDUSTRIALISATION

PCI Pharma Services

COMPANY SHOWCASE: PCI PHARMA SERVICES

PCI Pharma Services showcases its portfolio of drug delivery-relevant solutions, including: sterile fill-finish and lyophilisation; drug-device combination product design and development; packaging for injectables; and Speedsolutions™ supply chain simplification, and highlights plans for expansion.

TERUMO GLOBAL PARENTERAL CDMO – INTEGRATED INNOVATION

INDUSTRIALISATION

Terumo Medical Care Solutions

TERUMO GLOBAL PARENTERAL CDMO – INTEGRATED INNOVATION

Michele Guasti discusses the advantages that Terumo’s parenteral CDMO brings to customers due to its position as a single service provider from formulation to final product and its intimate understanding of Terumo’s range of prefillable polymer syringes.

INTERVIEW: DOUG BRYANS, BRYLLAN & JOHN MERHIGE, CREDENCE

INTERVIEW: DOUG BRYANS, BRYLLAN & JOHN MERHIGE, CREDENCE

Douglas Bryans and John Merhige discuss the changing needs of drug developers around novel dual-chamber and ready-to-use drug delivery devices, capacity and the delivery of complete solutions from CDMOs and device developers, anchored around the recently announced partnership between Credence MedSystems and Bryllan to provide these critical services.

NEW EXTRACTABLES DATA FOR OXYCAPT™ MULTILAYER PLASTIC VIAL FOR BIOLOGICS & GENE/CELL THERAPY

PREFILLED SYRINGES

Hiroki Hasegawa

Mitsubishi Gas Chemical

NEW EXTRACTABLES DATA FOR OXYCAPT™ MULTILAYER PLASTIC VIAL FOR BIOLOGICS & GENE/CELL THERAPY

Hiroki Hasegawa and Tomohiro Suzuki review the properties of OXYCAPT™, Mitsubishi Gas Chemical’s multilayer material for primary biologic packaging, and share the data from the latest study on OXYCAPT’s extractables profile.

PRIMARY PACKAGING CONSIDERATIONS FOR SUPPORTING COMPLIANCE TO ANNEX 1 REVISION

PREFILLED SYRINGES

Edouard Pagnoud

PRIMARY PACKAGING CONSIDERATIONS FOR SUPPORTING COMPLIANCE TO ANNEX 1 REVISION

Edouard Pagnoud, Estelle Verger and Benjamin Brocco look at the new requirements associated with EMA GMP Annex 1 revision regarding injectable primary packaging for ensuring sterility and safety, and consider how Aptar's PremiumFill^® can reduce the risk of contamination and defects.

RISING TO THE REGULATORY EVIDENCE CHALLENGE FOR HIGH-QUALITY COMBINATION PRODUCTS

PREFILLED SYRINGES

Victoria Morgan

West Pharmaceutical Services

RISING TO THE REGULATORY EVIDENCE CHALLENGE FOR HIGH-QUALITY COMBINATION PRODUCTS

Victoria Morgan and Stacy Gates-Rector explore how West is supporting pharma companies with packaging challenges through the supply of high-quality prefillable syringe plungers and provision of a highly co-ordinated technical documentation package.

BIOLOGIC INTEGRITY: MEASURING AND MANAGING THE HIDDEN LEACHABLES RISK FROM PFS ADHESIVE

INDUSTRIALISATION

Enrico Barichello

Stevanato Group

BIOLOGIC INTEGRITY: MEASURING AND MANAGING THE HIDDEN LEACHABLES RISK FROM PFS ADHESIVE

Enrico Barichello considers the often-overlooked influence of adhesive in the assembly of prefilled syringes and how the hidden risks can be managed and overcome.

1
2
3
…
37
Next

See what ondrugdelivery's readers and contributors think

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Top